As a part of the President’s fiscal year (FY) 2013 budget the U.S. Food and Drug Administration has asked a budget of $4.5 billion on medical product development, protect patients and ensure safety of the food supply to support public health.
Recently U.S. Food and Drug Administration has approved INLYTA(R) axitinib, a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) who have not responded to another drug for this type of cancer.
Antares Pharma has recently announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. The companies did not disclose specifics of the deal.
Recently, US Food and Drug Administration (FDA) has advised health providers not to use needle free injector devices to administer influenza vaccines, because so far no flu vaccines have been approved for administration using such devices, saying they are approved for only the measles, mumps and rubella vaccine.
The Indian drug industry could make huge gains as over $70 billion worth of drugs are expected to go off patent in the US, the world’s largest pharma market, in the next three years.
If a shareholder had invested about Rs 2,500 in Dr Reddy's Laboratories through the IPO in August 1986 and the rights issue of 1989, what do you think the holding would be worth today? A whopping Rs 40 lakh!
Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery and development in the life sciences industry, announced the extension of its agreement with sanofi-aventis for the licence of the DDI Predict 2009 Edition application.
3SBio Inc, a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis.
Like pharma giants Pfizer, Eli Lilly and Merck & Co, US biotechnology major Biogen Idec also doesn’t want to miss the India opportunity.
After witnessing a neutral budget last year, the Indian pharmaceutical industry has prepared itself again with its wish list for Budget 2010.
India might be shining for multinational drugmakers, but when it actually comes to introducing innovator drugs the $20 billion Indian pharma market is light years away.
Dishman Pharmaceuticals & Chemicals Ltd, a contract research & manufacturing services (CRAM) major, received the US Food and Drug Administration (USFDA) nod for producing Active Pharmaceutical Ingredients (API) at its Naroda facility here.
Troikaa Pharmaceuticals, a Gujarat based fast growing healthcare company, is likely to get US patent for its novel drug delivery form of Diclofenac injections-Dyanapar AQ.
* At least $1 billion incremental gains in export expected by 2014 Pakistan’s pharmaceutical sector has the potential to double its export in next five years provided pricing and contracting challenges are addressed in an efficient way, according to a draft of an official study.
Lilliputs keep cropping up here and there, but can Gulliver be ignored?
Few outside the recently developed township of Baddi in Himachal Pradesh will know Arun Rawat or his drug manufacturing company Kanha Biogenetic Laboratories. But this first-generation entrepreneur, who ventured into the drug-making business just five years ago, produces medicines for such majors as Wockhardt, Ajanta Pharma and Ind-Swift, to name a few.
Its pharma's turn to take center stage. Here's a look back at the highs and lows of what happened in 2009.
Cancer focused Biotechnology Company Gloucester Pharmaceuticals Inc. has agreed to be acquired by New Jersey firm Celgene Corp. for approximately $640 million, with $340 million paid in cash up front.
World’s second-largest generic drug maker Mylan, which held a majority stake in Ahmedabad based Concord Biotech through its subsidiary
Bangalore-based biopharmaceutical start-up Biovel Lifesciences is looking to exit from the life sciences space and is keen for an early outright buyout. Biovel has been in dialogue with several companies including Ranbaxy, Avesthagen, Shantha Biotechnics Ltd and Orchid Chemicals, it is learnt.
